What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

The POC testing market is set to reach $49 billion by 2018.

What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

The POC testing market is set to reach $49 billion by 2018.

Founder:
Associate Professor Dr. Cees Vermeer (presently retired) has dedicated 40 years of his scientific career to disease prevention by optimal nutrition. His research has formed the basis for the Triage principle: long term minimal micronutrient insufficiencies form a strong risk factor for age-related diseases. He is a Key Opinion Leader in the field of vitamin K and author of over 420 papers in the international scientific press.

CEO:
Drs. Mehrdad Omidvar has more than 24 years working experience (national and international) in several fields: Care & Cure, Investment, Pharma, R&D, Innovation, Life Science, E-health, Medical Device, POC and IVD, Knowledge Valorisation, Clinical Nutrition and Contract Research Organization (CRO). He was also Director UAE of Maastricht University and Director Business Development at CARIM (School for Cardiovascular Diseases, Maastricht University).

CSO:
Professor Dr. Stephane Heymans combines clinics and research in Cardiology since 2003. He leads a clinical care and research program in heart failure, in particular non-ischemic dilated cardiomyopathy, myocarditis and heart failure with preserved ejection fraction at the Maastricht University Medical Centre. His research looks for innovative techniques for the early diagnosis and refined therapies of these cardiovascular diseases. Genetics, omics, fibrosis and immunology are his main topics of research. Appointed as Professor of Cardiomyopathies within the Netherlands Heart Institute, the Maastricht University, and the University of Leuven.

Vice President R&D:
Dr. Pamela Kleikers studied Medicine at Maastricht University. After obtaining her medical degree in 2009, she started to work at the Atrium Medisch Centrum in Heerlen. In 2014 she got her PhD at Maastricht University, at the department of Pharmacology. She continued working as a postdoctoral researcher at the department of Pharmacology and Personalised Medicine. Next to the research activities, Dr. Kleikers was also involved in teaching and supervision of (bio)medical students of Maastricht University.

Operational Director:
Mrs. Marjo Knapen, BSc. She joined the VitaK Innovation in Life Sciences in 2001, and before that she has worked for 14 years at the Maastricht University. She is author in more than 85 publications in the international scientific literature. She is also heading the International Center for Human Intervention Studies (ICHIS).

International Commercial Director:
Mrs. Ling Leonard has more than 25 years working experience (national and international) in several fields: Care & Cure, Innovation and Medical Device, specialized in cardiopulmonary products. After obtaining her MBA degree at the Oklahoma City University, she studied Public Accounting in the  USA.

Head office:
Oxfordlaan 55
6229 EV Maastricht
The Netherlands
T: +31 (0)43 388 5926

Laboratories:
Oxfordlaan 70
6229 EV Maastricht
The Netherlands
E: info@vitak.com